Panacea Acquisition Corp. II (PANA): Price and Financial Metrics
GET POWR RATINGS... FREE!
PANA Stock Price Chart Interactive Chart >
PANA Price/Volume Stats
|Current price||$10.01||52-week high||$10.23|
|Prev. close||$10.00||52-week low||$9.90|
|Day high||$10.01||Avg. volume||28,902|
|50-day MA||$0.00||Dividend yield||N/A|
|200-day MA||$0.00||Market Cap||205.21M|
Panacea Acquisition Corp. II (PANA) Company Bio
Panacea Acquisition Corp. II intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the biotechnology sector. The company was incorporated in 2021 and is based in San Francisco, California.
PANA Latest News Stream
|Loading, please wait...|
PANA Latest Social Stream
View Full PANA Social Stream
Latest PANA News From Around the Web
Below are the latest news stories about Panacea Acquisition Corp II that investors may wish to consider to help them evaluate PANA as an investment opportunity.
SAN FRANCISCO, CA, April 06, 2021 (GLOBE NEWSWIRE) -- Panacea Acquisition Corp. II (the “Company”), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced the pricing of its initial public offering of 15,000,000 Class A ordinary shares at a price of $10.00 per share. The Company is sponsored by EcoR1 Panacea Holdings II, LLC, an affiliate of EcoR1 Capital, LLC. While the Company may pursue an initial business combination target in any industry or geographic location, it intends to focus its search for a target business operating in the biotechnology sector that is domiciled in North America or Europe. The Class A ordinary shares are ...
Panacea Announces Effectiveness of Registration Statement for Proposed Business Combination with Nuvation Bio
Panacea Acquisition Corp., a Delaware corporation (the "Company") (NYSE: PANA.U, PANA, PANA WS), announced today that its registration statement on Form S-4 (File No. 333-250036) (as amended, the "Registration Statement"), relating to the previously announced business combination (the "Business Combination") with Nuvation Bio Inc. ("Nuvation Bio"), has been declared effective by the U.S. Securities and Exchange Commission ("SEC") and that it has commenced mailing the definitive proxy statement/prospectus relating to the Special Meeting (the "Special Meeting") of the Company’s stockholders to be held on February 9, 2021 in connection with the Business Combination. The definitive proxy statement/prospectus is being mailed to the Company’s stockholders of record as of the close of business...
Nuvation Bio and Panacea Announce Business Combination Agreement, Creating a Publicly Listed Leader in Oncology Drug Development
Nuvation Bio Inc., a biopharmaceutical company focused on revolutionizing cancer treatment by discovering, developing and delivering therapies that tackle some of the greatest needs in oncology, and Panacea Acquisition Corp. (NYSE: PANA), a special purpose acquisition company (SPAC) sponsored by EcoR1 Capital, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, Panacea will be renamed Nuvation Bio Inc. (the Combined Company); its common stock is expected to remain listed on the New York Stock Exchange (NYSE) under the new ticker symbol "NUVB."
PANA Price Returns